Neoadjuvant Anti-PD1 in HCC

Sponsor
Dr Tan-to CHEUNG
Study ID
NCT05471674
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
  • Hepatectomy — PROCEDURE
    Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab

Study Details

This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.

Key Dates

Start date
Jul 3, 2020
Status verified
Jan 2023
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment

Primary Outcome Measure

Pathological tumour response rate [ Time Frame: After surgery (normally 6 weeks after the start of nivolumab) ]

Related Studies